Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
19
5
5
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.3%
1 terminated/withdrawn out of 19 trials
92.9%
+6.4% vs industry average
5%
1 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully
Role: lead
Evaluation of the Acceptability and Impact of a Sexual Health Screening and Prevention Program for Vulnerable Women
Role: lead
Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France
Role: lead
Switch From Etravirine to Doravirine as a Part of Antiretroviral Combination
Role: lead
Adipose Tissue After Switch to Doravirine
Role: lead
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
Role: lead
Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV
Role: lead
Pathophysiological Study of Adipose Tissue of Patients Infected With HIV
Role: lead
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
Role: lead
Optimisation of Care in Vulnerable HIV Infected Individuals
Role: lead
COVID-19 and HIV Patients
Role: lead
Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir
Role: lead
COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease
Role: lead
Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)
Role: lead
Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)
Role: lead
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
Role: lead
Pilot Study of HIV and Hepatitis B and C Screening in Surgery
Role: lead
Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients
Role: lead
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Role: lead
All 19 trials loaded